Immunological characteristics of patients with HIV-DLBCL and their matched controls at DLBCL diagnosis
| . | Patients . | Matched controls . | P value . |
|---|---|---|---|
| n | 13 | 13 | |
| Immunoglobulin | |||
| IgG (g/L) | 12.6 (10.2- 15.1) | 14.7 (11.9- 18.5) | .03 |
| IgA (g/L) | 1.7 (1.2-2.3) | 2.3 (1.9-2.7) | .22 |
| IgM (g/L) | 0.7 (0.4-0.8) | 0.9 (0.6-1.2) | .33 |
| CD45+ leucocytes (× 109/L) | 1.52 (1.22- 2.03) | 1.67 (1.31- 1.96) | .84 |
| T lymphocytes | |||
| CD3+ T lymphocytes (× 109/L) | 1.23 (0.9- 1.44) | 1.15 (0.91- 1.37) | .79 |
| CD3+CD4+ T lymphocytes (× 109/L) | 0.43 (0.28- 0.59) | 0.42 (0.33- 0.50) | .74 |
| CD3+CD8+ T lymphocytes (× 109/L) | 0.66 (0.40- 1.1) | 0.62 (0.51- 0.81) | .31 |
| CD4+:CD8+ ratio | 0.7 (0.4-0.9) | 0.7 (0.5-1.1) | .73 |
| NK lymphocytes | |||
| NK lymphocytes (× 109/L) | 0.14 (0.10- 0.22) | 0.16 (0.13- 0.30) | .64 |
| B lymphocytes | |||
| CD19+ B lymphocytes (× 109/L) | 0.17 (0.05- 0.4) | 0.23 (0.12- 0.29) | .86 |
| CD19+IgD+CD27− among B lymphocytes (%) | 84.5 (75.0- 90.0) | 70.0 (61.0- 79.0) | .17 |
| CD19+IgD+CD27+ among B lymphocytes (%) | 4.5 (2.0-9.8) | 7.0 (3.0-19.0) | .29 |
| CD19+IgD−CD27+ among B lymphocytes (%) | 6.0 (3.8- 10.8) | 15.0 (13.0- 20.0) | .37 |
| Cytokines | |||
| IL-6 blood level (pg/mL) | 9.2 (0.0- 38.6) | 5.4 (1.0-35.0) | .78 |
| IL-10 blood level (pg/mL) | 23.7 (11.6- 36.9) | 4.4 (3.9-12.0) | .001 |
| BAFF blood level (pg/mL) | 1114.0 (850.2- 1880.8) | 426.5 (362.0- 581.0) | .016 |
| . | Patients . | Matched controls . | P value . |
|---|---|---|---|
| n | 13 | 13 | |
| Immunoglobulin | |||
| IgG (g/L) | 12.6 (10.2- 15.1) | 14.7 (11.9- 18.5) | .03 |
| IgA (g/L) | 1.7 (1.2-2.3) | 2.3 (1.9-2.7) | .22 |
| IgM (g/L) | 0.7 (0.4-0.8) | 0.9 (0.6-1.2) | .33 |
| CD45+ leucocytes (× 109/L) | 1.52 (1.22- 2.03) | 1.67 (1.31- 1.96) | .84 |
| T lymphocytes | |||
| CD3+ T lymphocytes (× 109/L) | 1.23 (0.9- 1.44) | 1.15 (0.91- 1.37) | .79 |
| CD3+CD4+ T lymphocytes (× 109/L) | 0.43 (0.28- 0.59) | 0.42 (0.33- 0.50) | .74 |
| CD3+CD8+ T lymphocytes (× 109/L) | 0.66 (0.40- 1.1) | 0.62 (0.51- 0.81) | .31 |
| CD4+:CD8+ ratio | 0.7 (0.4-0.9) | 0.7 (0.5-1.1) | .73 |
| NK lymphocytes | |||
| NK lymphocytes (× 109/L) | 0.14 (0.10- 0.22) | 0.16 (0.13- 0.30) | .64 |
| B lymphocytes | |||
| CD19+ B lymphocytes (× 109/L) | 0.17 (0.05- 0.4) | 0.23 (0.12- 0.29) | .86 |
| CD19+IgD+CD27− among B lymphocytes (%) | 84.5 (75.0- 90.0) | 70.0 (61.0- 79.0) | .17 |
| CD19+IgD+CD27+ among B lymphocytes (%) | 4.5 (2.0-9.8) | 7.0 (3.0-19.0) | .29 |
| CD19+IgD−CD27+ among B lymphocytes (%) | 6.0 (3.8- 10.8) | 15.0 (13.0- 20.0) | .37 |
| Cytokines | |||
| IL-6 blood level (pg/mL) | 9.2 (0.0- 38.6) | 5.4 (1.0-35.0) | .78 |
| IL-10 blood level (pg/mL) | 23.7 (11.6- 36.9) | 4.4 (3.9-12.0) | .001 |
| BAFF blood level (pg/mL) | 1114.0 (850.2- 1880.8) | 426.5 (362.0- 581.0) | .016 |
The results are presented as median [IQR].